Clinical Guide: Selective Laser Trabeculoplasty (SLT)

1. Comprehensive Introduction & Overview

Selective Laser Trabeculoplasty (SLT) represents a paradigm shift in the management of glaucoma and ocular hypertension. As a non-invasive, non-thermal, and repeatable laser procedure, SLT has become a first-line therapy for lowering intraocular pressure (IOP). Unlike its predecessor, Argon Laser Trabeculoplasty (ALT), which utilized thermal damage to induce scarring and tension in the trabecular meshwork, SLT employs a Q-switched, frequency-doubled Nd:YAG laser (532 nm) to selectively target pigmented cells.

The primary objective of SLT is to stimulate a biological response in the trabecular meshwork (TM), effectively enhancing aqueous humor outflow without causing collateral structural damage. Because the procedure is "selective," it spares the non-pigmented TM cells, allowing for repeated treatments if necessary—a significant clinical advantage over traditional surgical interventions.

2. Technical Specifications & Mechanism of Action

The Photothermolysis Principle

SLT operates on the principle of selective photothermolysis. By delivering a low-energy pulse (typically 0.6–1.2 mJ) over a very short duration (3 nanoseconds), the laser energy is absorbed exclusively by the melanin-containing cells within the trabecular meshwork.

The Biological Cascade

1. Targeting: The 532 nm wavelength is absorbed by the pigmented phagocytes in the TM.
2. Cellular Activation: The energy pulse triggers an upregulation of cytokines (IL-1, IL-6, TNF-alpha).
3. Macrophage Recruitment: The inflammatory response recruits macrophages to the meshwork.
4. Remodeling: These macrophages "cleanse" the TM of debris and extracellular matrix deposits, effectively increasing the facility of outflow.
5. Pressure Reduction: Enhanced outflow leads to a significant decrease in intraocular pressure, typically within 4 to 12 weeks post-procedure.

Laser Specifications

3. Clinical Indications & Usage

SLT is indicated for patients who require a reduction in IOP to prevent or slow the progression of glaucomatous optic neuropathy.

Primary Indications

• Primary Open-Angle Glaucoma (POAG): Often used as a first-line therapy (as supported by the LiGHT trial).
• Ocular Hypertension (OHT): For patients at high risk of conversion to glaucoma.
• Pseudoexfoliative Glaucoma: Generally shows a robust response due to high pigment density.
• Pigmentary Glaucoma: Effective, though requires lower energy levels to prevent pressure spikes.
• Patients Intolerant to Topical Medications: Ideal for those suffering from ocular surface disease (OSD) caused by benzalkonium chloride (BAK) in eye drops.

Clinical Contraindications

• Angle-Closure Glaucoma: SLT requires visualization of the TM.
• Secondary Glaucomas (Inflammatory/Uveitic): Inflammation may exacerbate the underlying condition.
• Severe Corneal Opacities: Obstructs laser delivery.
• Neovascular Glaucoma: High risk of hemorrhage.

4. Pre-Operative Preparation & Procedure Protocol

Patient Preparation

1. Informed Consent: Discuss the potential for IOP spikes and the variability of individual response.
2. Topical Anesthesia: Instillation of proparacaine or tetracaine.
3. Miosis: Often, pilocarpine is administered to tighten the TM and improve visualization, though this is clinician-dependent.
4. Goniolens Placement: A specialized lens (e.g., Abraham or Latina lens) is placed on the eye to allow visualization of the anterior chamber angle.

The Procedural Steps

• Step 1: Alignment: Focus the aiming beam on the trabecular meshwork, specifically targeting the posterior aspect of the pigmented meshwork.
• Step 2: Titration: Start with an energy level of 0.8 mJ. If no bubble formation (cavitation) is observed, increase by 0.1 mJ increments. If large "champagne bubbles" occur, decrease energy.
• Step 3: Application: Deliver approximately 50–60 non-overlapping spots over 180 degrees (half-treatment) or 100–120 spots over 360 degrees.
• Step 4: Completion: Remove the lens, rinse the eye, and perform a post-operative IOP check 30–60 minutes later.

5. Post-Operative Recovery Protocol

The recovery from SLT is generally rapid, but requires careful monitoring.

• Immediate Post-Op: Monitor IOP for 1–2 hours to rule out an acute pressure spike.
• Medication: Often, a short course of topical NSAIDs (e.g., ketorolac or bromfenac) is prescribed for 3–5 days to manage mild inflammation. Steroids are generally avoided or used sparingly to prevent blunting the biological response.
• Follow-up:
  • 1-week post-op: IOP check.
  • 4–6 weeks post-op: Full assessment of clinical efficacy (IOP reduction).
• Activity Restrictions: None. Patients may return to normal activities immediately.

6. Risks, Side Effects, and Complications

While SLT is considered very safe, clinicians must be aware of potential adverse events:

• IOP Spike: The most common complication, occurring in 5–10% of patients. Usually transient and managed with topical aqueous suppressants.
• Anterior Uveitis: Mild, self-limiting inflammation.
• Peripheral Anterior Synechiae (PAS): Rare, usually associated with high-energy settings.
• Corneal Abrasion: From the goniolens placement.
• Lack of Efficacy: Approximately 10–20% of patients may be "non-responders" due to individual biological variance in TM cellularity.

7. Alternative Treatments

When SLT is insufficient or contraindicated, other modalities include:

1. Pharmacotherapy: Prostaglandin analogs (first-line), beta-blockers, and alpha-agonists.
2. Micro-Invasive Glaucoma Surgery (MIGS): iStent, Hydrus, or Omni procedures.
3. Traditional Filtering Surgery: Trabeculectomy or Glaucoma Drainage Devices (GDD) for advanced or refractory cases.
4. Cyclodestructive Procedures: Transscleral Cyclophotocoagulation (TSCPC) for end-stage pain management.

8. Massive FAQ Section

1. How long does the IOP-lowering effect of SLT last?

Studies indicate that the effect typically lasts 1 to 5 years. However, because SLT is repeatable, the treatment can be re-administered if the pressure begins to rise again.

2. Does SLT hurt?

The procedure is virtually painless. Patients may feel a slight sensation of pressure from the goniolens, but the laser pulses themselves are not felt.

3. Can I stop using my glaucoma eye drops after SLT?

In many cases, yes. The LiGHT trial demonstrated that a significant percentage of patients could remain drop-free for several years post-SLT. However, this depends on individual IOP targets.

4. What is the success rate of SLT?

Success is typically defined as a 20% or greater reduction in IOP. Clinical literature reports success rates ranging from 75% to 85% in treatment-naive patients.

5. Why is SLT preferred over ALT?

SLT is non-thermal, meaning it does not cause scarring. This allows for repeat procedures, which was not feasible with the older ALT technology.

6. Can SLT be performed on both eyes at once?

Yes, it is common to perform SLT on both eyes during a single office visit.

7. What should I do if I see blurry vision after the procedure?

Mild, transient blurring is common due to the gel used with the goniolens. If vision remains blurred for more than 24 hours, contact your ophthalmologist immediately.

8. Is SLT covered by insurance?

In most jurisdictions, including the United States, SLT is a standard, covered procedure for the treatment of glaucoma and ocular hypertension.

9. What if I have narrow angles?

SLT is generally contraindicated in cases of primary angle-closure glaucoma because the laser cannot reach the trabecular meshwork. Laser Peripheral Iridotomy (LPI) is usually the preferred approach for narrow angles.

10. Does age affect the outcome of SLT?

While SLT is effective across all ages, some studies suggest that older patients may have a slightly higher rate of success, potentially due to differences in TM pigmentation and cellular response.

Conclusion

Selective Laser Trabeculoplasty has solidified its position as a cornerstone of modern glaucoma care. By leveraging the body's own biological processes to improve aqueous outflow, it provides a safe, repeatable, and effective alternative to the lifelong burden of topical medications. As clinical techniques evolve, the shift toward earlier intervention with SLT continues to improve the quality of life and long-term visual prognosis for millions of glaucoma patients worldwide.